Financial Ratios Edwards Lifesciences Corporation
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.10 USD | -0.88% |
|
-2.04% | -2.52% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 11.99 | 12.6 | 13.34 | 12.25 | 8.26 | |||||
Return on Total Capital | 16.3 | 16.81 | 17.2 | 15.54 | 10.19 | |||||
Return On Equity % | 18.88 | 28.88 | 26.14 | 22.34 | 16.64 | |||||
Return on Common Equity | 18.88 | 28.88 | 26.14 | 22.52 | 16.83 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 75.36 | 76.13 | 79.96 | 77.02 | 79.46 | |||||
SG&A Margin | 28.01 | 28.55 | 29.1 | 30.37 | 32.88 | |||||
EBITDA Margin % | 32.45 | 32.9 | 35.89 | 31.22 | 30.07 | |||||
EBITA Margin % | 30.13 | 30.47 | 33.4 | 28.91 | 27.32 | |||||
EBIT Margin % | 30.01 | 30.32 | 33.29 | 28.81 | 27.22 | |||||
Income From Continuing Operations Margin % | 18.77 | 28.73 | 28.28 | 23.3 | 25.66 | |||||
Net Income Margin % | 18.77 | 28.73 | 28.28 | 23.35 | 76.75 | |||||
Net Avail. For Common Margin % | 18.77 | 28.73 | 28.28 | 23.35 | 25.75 | |||||
Normalized Net Income Margin | 19.04 | 19.2 | 21.19 | 18.8 | 18.42 | |||||
Levered Free Cash Flow Margin | 8.52 | 19.28 | 17.33 | 12.51 | 24.83 | |||||
Unlevered Free Cash Flow Margin | 8.75 | 19.5 | 17.56 | 12.69 | 25.06 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.64 | 0.66 | 0.64 | 0.68 | 0.49 | |||||
Fixed Assets Turnover | 3.34 | 3.35 | 3.2 | 3.37 | 3.14 | |||||
Receivables Turnover (Average Receivables) | 8.29 | 9.54 | 8.79 | 8.47 | 7.88 | |||||
Inventory Turnover (Average Inventory) | 1.5 | 1.63 | 1.35 | 1.35 | 1.12 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.46 | 3.08 | 3.03 | 3.38 | 4.18 | |||||
Quick Ratio | 2.24 | 2.06 | 1.87 | 2.08 | 3.12 | |||||
Operating Cash Flow to Current Liabilities | 1.18 | 1.68 | 1.19 | 0.75 | 0.36 | |||||
Days Sales Outstanding (Average Receivables) | 44.15 | 38.25 | 41.54 | 43.1 | 46.45 | |||||
Days Outstanding Inventory (Average Inventory) | 244.41 | 223.43 | 271.04 | 270.31 | 325.91 | |||||
Average Days Payable Outstanding | 55.53 | 62.37 | 60.42 | 44.01 | 54.03 | |||||
Cash Conversion Cycle (Average Days) | 233.02 | 199.31 | 252.17 | 269.4 | 318.33 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 15.19 | 11.83 | 11.91 | 10.34 | 6.96 | |||||
Total Debt / Total Capital | 13.19 | 10.58 | 10.64 | 9.37 | 6.5 | |||||
LT Debt/Equity | 14.6 | 11.39 | 11.47 | 9.97 | 6.72 | |||||
Long-Term Debt / Total Capital | 12.67 | 10.19 | 10.25 | 9.04 | 6.29 | |||||
Total Liabilities / Total Assets | 36.79 | 31.36 | 29.98 | 28.24 | 22.92 | |||||
EBIT / Interest Expense | 83.3 | 86.22 | 93.33 | 98.28 | 74.78 | |||||
EBITDA / Interest Expense | 92.02 | 95.16 | 102.1 | 108.23 | 84.04 | |||||
(EBITDA - Capex) / Interest Expense | 66.26 | 77.46 | 89.36 | 93.85 | 71.29 | |||||
Total Debt / EBITDA | 0.48 | 0.39 | 0.35 | 0.36 | 0.42 | |||||
Net Debt / EBITDA | -0.49 | -0.44 | -0.27 | -0.5 | -1.97 | |||||
Total Debt / (EBITDA - Capex) | 0.66 | 0.48 | 0.4 | 0.42 | 0.5 | |||||
Net Debt / (EBITDA - Capex) | -0.68 | -0.54 | -0.31 | -0.57 | -2.32 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 0.88 | 19.29 | 2.86 | 11.56 | 8.57 | |||||
Gross Profit, 1 Yr. Growth % | 2.23 | 20.51 | 8.03 | 7.47 | 7.2 | |||||
EBITDA, 1 Yr. Growth % | 7.04 | 20.93 | 12.21 | -2.94 | 0.22 | |||||
EBITA, 1 Yr. Growth % | 6.14 | 20.63 | 12.76 | -3.43 | -0.22 | |||||
EBIT, 1 Yr. Growth % | 6.1 | 20.54 | 12.95 | -3.47 | -0.45 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -21.35 | 82.55 | 1.25 | -8.05 | 14.43 | |||||
Net Income, 1 Yr. Growth % | -21.35 | 82.55 | 1.25 | -7.85 | 197.68 | |||||
Normalized Net Income, 1 Yr. Growth % | 5.96 | 20.29 | 13.54 | -1.07 | 3.07 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -20.73 | 83.08 | 2.52 | -5.74 | 16.42 | |||||
Accounts Receivable, 1 Yr. Growth % | -5.33 | 13.14 | 10.44 | 20.54 | -21.05 | |||||
Inventory, 1 Yr. Growth % | 25.18 | -9.42 | 20.48 | 33.43 | 20.28 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 30.6 | 10.02 | 5.27 | 6.86 | 6.49 | |||||
Total Assets, 1 Yr. Growth % | 11.54 | 17.49 | -2.47 | 12.91 | 39.43 | |||||
Tangible Book Value, 1 Yr. Growth % | 16.1 | 41.53 | 0.29 | 14.02 | 37.99 | |||||
Common Equity, 1 Yr. Growth % | 10.27 | 27.58 | -0.5 | 14.52 | 50.35 | |||||
Cash From Operations, 1 Yr. Growth % | -10.87 | 64.29 | -29.67 | -26.47 | -39.46 | |||||
Capital Expenditures, 1 Yr. Growth % | 59.98 | -19.95 | -24.92 | 3.43 | -0.24 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -27.87 | 169.96 | -7.53 | -19.51 | 129.03 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -27.77 | 166.01 | -7.39 | -19.37 | 126.89 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 8.55 | 9.7 | 10.77 | 7.13 | 10.39 | |||||
Gross Profit, 2 Yr. CAGR % | 8.98 | 10.99 | 14.1 | 7.75 | 7.47 | |||||
EBITDA, 2 Yr. CAGR % | 11.24 | 13.86 | 16.49 | 4.36 | -1.36 | |||||
EBITA, 2 Yr. CAGR % | 10.86 | 13.24 | 16.63 | 4.35 | -1.89 | |||||
EBIT, 2 Yr. CAGR % | 10.76 | 13.18 | 16.68 | 4.42 | -2 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 6.78 | 19.82 | 35.95 | -3.51 | 2.68 | |||||
Net Income, 2 Yr. CAGR % | 6.78 | 19.82 | 35.95 | -3.41 | 65.62 | |||||
Normalized Net Income, 2 Yr. CAGR % | 11.13 | 12.99 | 16.87 | 6.21 | 1.4 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 7.26 | 20.47 | 37 | -1.7 | 5.06 | |||||
Accounts Receivable, 2 Yr. CAGR % | 6.13 | 3.49 | 11.78 | 15.38 | -2.67 | |||||
Inventory, 2 Yr. CAGR % | 14.97 | 6.48 | 4.46 | 26.79 | 11.41 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 31.03 | 19.87 | 7.62 | 6.06 | 1.7 | |||||
Total Assets, 2 Yr. CAGR % | 16.59 | 14.48 | 7.04 | 4.94 | 25.47 | |||||
Tangible Book Value, 2 Yr. CAGR % | 34.97 | 28.18 | 19.14 | 6.94 | 27.16 | |||||
Common Equity, 2 Yr. CAGR % | 20.69 | 18.61 | 12.67 | 6.75 | 31.22 | |||||
Cash From Operations, 2 Yr. CAGR % | 6.66 | 21.01 | 7.49 | -28.09 | -33.28 | |||||
Capital Expenditures, 2 Yr. CAGR % | 30.58 | 13.17 | -22.48 | -11.88 | 1.58 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -13.05 | 39.71 | 58 | -13.72 | 31.88 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -13.53 | 38.78 | 56.95 | -13.59 | 31.47 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 8.49 | 12.02 | 7.37 | 11.04 | 1.3 | |||||
Gross Profit, 3 Yr. CAGR % | 8.9 | 12.69 | 10 | 11.84 | 2.76 | |||||
EBITDA, 3 Yr. CAGR % | 8.83 | 14.38 | 13.31 | 9.61 | -1.68 | |||||
EBITA, 3 Yr. CAGR % | 8.66 | 14.03 | 13.08 | 9.52 | -2.31 | |||||
EBIT, 3 Yr. CAGR % | 8.78 | 13.93 | 13.1 | 9.54 | -2.27 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 12.16 | 27.68 | 13.28 | 19.34 | -2.43 | |||||
Net Income, 3 Yr. CAGR % | 12.16 | 27.68 | 13.28 | 19.42 | 40.56 | |||||
Normalized Net Income, 3 Yr. CAGR % | 9.6 | 14.11 | 13.17 | 10.57 | 0.03 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 13.04 | 28.18 | 14.16 | 20.95 | -0.56 | |||||
Accounts Receivable, 3 Yr. CAGR % | 5.46 | 8.41 | 5.76 | 14.63 | 1.52 | |||||
Inventory, 3 Yr. CAGR % | 13.08 | 6.18 | 10.96 | 13.34 | 14.35 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 29.89 | 23.62 | 14.79 | 7.37 | 2.88 | |||||
Total Assets, 3 Yr. CAGR % | 8.5 | 16.89 | 8.52 | 8.96 | 15.37 | |||||
Tangible Book Value, 3 Yr. CAGR % | 31.12 | 37.12 | 18.12 | 17.41 | 17.49 | |||||
Common Equity, 3 Yr. CAGR % | 15.66 | 22.94 | 11.86 | 13.28 | 19.66 | |||||
Cash From Operations, 3 Yr. CAGR % | 1.75 | 23.18 | 0.98 | -5.29 | -32.1 | |||||
Capital Expenditures, 3 Yr. CAGR % | 34.28 | 10.93 | -1.3 | -14.66 | -8.16 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -16.38 | 26.84 | 21.76 | 26.19 | 10.22 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -16.28 | 25.76 | 21.27 | 25.71 | 10.13 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 11.96 | 12.04 | 9.4 | 10.03 | 4.58 | |||||
Gross Profit, 5 Yr. CAGR % | 11.99 | 12.96 | 10.95 | 10.69 | 5.97 | |||||
EBITDA, 5 Yr. CAGR % | 14.97 | 14.09 | 11.83 | 10.26 | 4.26 | |||||
EBITA, 5 Yr. CAGR % | 15.25 | 14.03 | 11.78 | 10.05 | 3.64 | |||||
EBIT, 5 Yr. CAGR % | 15.41 | 14.13 | 11.88 | 10.03 | 3.64 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 10.72 | 21.42 | 21.13 | 14.14 | 5.92 | |||||
Net Income, 5 Yr. CAGR % | 10.72 | 21.42 | 21.13 | 14.19 | 31.87 | |||||
Normalized Net Income, 5 Yr. CAGR % | 16.2 | 14.8 | 12.45 | 10.8 | 4.95 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 11.63 | 22.3 | 22.08 | 15.27 | 7.37 | |||||
Accounts Receivable, 5 Yr. CAGR % | 10.29 | 9.76 | 7.95 | 11.15 | 2.3 | |||||
Inventory, 5 Yr. CAGR % | 18.74 | 12.88 | 9.55 | 13.99 | 11.14 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 25.29 | 23.09 | 20.48 | 16.27 | 9.36 | |||||
Total Assets, 5 Yr. CAGR % | 12.28 | 13.52 | 7.91 | 11.95 | 15.01 | |||||
Tangible Book Value, 5 Yr. CAGR % | 12.96 | 19.43 | 26.19 | 24.14 | 21.65 | |||||
Common Equity, 5 Yr. CAGR % | 12.82 | 17.38 | 14.46 | 16.19 | 19.24 | |||||
Cash From Operations, 5 Yr. CAGR % | 13.91 | 19.72 | 4.01 | -0.68 | -14.44 | |||||
Capital Expenditures, 5 Yr. CAGR % | 31.71 | 13.09 | 7.79 | 1.17 | -0.16 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -2.28 | 25.71 | 7.86 | 8.72 | 21.18 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -2.27 | 25.07 | 7.65 | 8.23 | 20.8 |
- Stock Market
- Equities
- EW Stock
- Financials Edwards Lifesciences Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















